We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Rabies Diagnostic Tool Validated for Field Surveillance

By LabMedica International staff writers
Posted on 16 Nov 2016
Rabies is a viral zoonotic encephalomyelitis transmitted to humans after exposure to infected mammals, mainly dogs, through bites, scratches or licks on damaged skin or mucous membranes.

The high fatality and burden of rabies stands in contrast to the very low performance of laboratory-based surveillance in resource-challenged countries. More...
The absence of reliable human and animal rabies incidence data ultimately result in neglect of disease prevention and control and the perpetuation of rabies virus (RABV) transmission despite the existence of powerful management tools.

An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) tested 48 samples from dogs and in the reference laboratory setting, a total of 73 samples was tested, representing a wide diversity of RABV in terms of animal species tested (13 different species), geographical origin of isolates with special emphasis on Africa, and different phylogenetic clades.

The team evaluated a rapid immunodiagnostic test (RIDT) in comparison with the standard fluorescent antibody test (FAT) and confirmed the detection of the viral ribonucleic acid (RNA) by real time reverse transcription polymerase chain reaction (RT-qPCR). The RIDT Anigen test, was a chromatographic immunoassay-based on lateral flow technology (BioNote, Inc, Hwaseong, Republic of Korea). Viral RNA detection was performed using a one-step dual combine pan-lyssavirus RT-qPCR assay.

The scientists reported that for the majority of the total sample size of 121 samples tested, the RIDT was successfully performed, with the presence of a line clearly visible in the control zone after five to 15 minutes of migration once the sample was deposited. Compared to the gold standard FAT, the RIDT demonstrated an accordance of 95%. The specificity was 93.3% with only two false positive results among the 30 FAT negative specimens. A total of 51 samples were tested for viral RNA detection using RT-qPCR on the Anigen test strip, which were previously found positive for the post-mortem diagnosis of rabies. When compared to the FAT Whatman card, RT-qPCR performed on the Anigen test strip exhibited a sensitivity of 80.6%.

The authors concluded that the RIDT shows excellent performance qualities both in regard to user friendliness and reliability of the result. In addition, the test cassettes can be used as a vehicle to ship viral RNA to reference laboratories for further laboratory confirmation of the diagnosis and for epidemiological investigations using nucleotide sequencing. The potential for satisfactory use in remote locations is therefore very high to improve the global knowledge of rabies epidemiology. The study was published on October 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Swiss Tropical and Public Health Institute
BioNote

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
HbA1c Test
HbA1c Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.